3E Bioventures Capital
本草资本
elsewhere's corpus does not cover 3E Bioventures Capital directly. The retrieved material mentions the fund only in passing—as a co-investor alongside others in two 2024 deals (Angtuo and Saiqiao Biotech) —without providing its own founding story, team, strategy, or scale. No entity card or dedicated article about the fund appears in the bundle.
AI-generated — may contain errors, please verify.
3E Bioventures CapitalFund
本草资本
渲染中…
Mentioned in 3 articles
Coverage
MaKe | MaHui Member CytoBridge Bio Closes Nearly RMB 200 Million Series B Round; Source Code Capital Led Pre-B Round
Rongbao | Major Acquisition in Innovative Drugs; Laser Chips, Quantum Computing, and Global Payment Platform Secure New Funding
"Every step forward feels like a bloom."
Onto Innovation Completes Over $50 Million Series A Financing to Accelerate Deep Pipeline Expansion in Nucleic Acid Drugs
Focused on drug development based on antisense oligonucleotide technology.
